AstraZeneca PLC (AZN) Stock

AstraZeneca PLC trades at a P/E ratio of 28.05, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 15.50 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.93 suggests the stock may be undervalued relative to its growth rate.

With a beta of 0.17, AstraZeneca PLC is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 5.28 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

AstraZeneca PLC achieves a profit margin of 14.10%, meaning it retains $14.10 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 27.90% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 19.80% and ROA at 8.16%, the company generates strong returns on invested capital.

AstraZeneca PLC's revenue grew by 7.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 33.60% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

AstraZeneca PLC offers a dividend yield of 2.22%, paying $3.10 per share annually. This above-average yield of 2-4% provides meaningful income while still allowing the company to reinvest for growth. It compares favorably to the S&P 500 average and offers competitive returns versus bonds in the current rate environment. To receive the next dividend, shares must be purchased before the ex-dividend date of 2/21/2025.

The dividend sustainability can be assessed through the payout ratio - AstraZeneca PLC pays $3.10 per share in dividends against earnings of $2.49 per share, resulting in a payout ratio of 100.00%. This very high payout exceeding 90% raises sustainability concerns, as nearly all earnings go to dividends. Any earnings decline could force a dividend cut. The next dividend payment is scheduled for 3/24/2025.

AstraZeneca PLC has a market capitalization of $216.57B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 3.10B shares outstanding, the company's ownership is widely distributed. As a major player in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.

AstraZeneca PLC's book value per share is $26.48, while the current stock price is $72.66, resulting in a price-to-book (P/B) ratio of 2.74. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

12 analysts cover AZN with 83% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $84.18 implies 15.9% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:4 Strong Buy, 6 Buy, 2 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.